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Background: Cigarette smoke contains free radicals and an have adverse effect to the immune system.
Supplementation of palm oil vitamin E (palmvitee), is known has antioxidant properties is thought to be beneficial
for system immune protection against free radicals activity. The objective of the study was to determine the effect
of palmvitee supplementation on immune response in smokers.
Methods: This study involved a group of smokers and nonsmokers who received 200 mg/day palmvitee and placebo
for the control group. Blood samples were taken at 0, 12 and 24 weeks of supplementation. Plasma tocopherol and
tocotrienol were determined by HPLC, lymphocyte proliferation by lymphocyte transformation test (LTT) and
enumeration of lymphocytes T and B cells by flow cytometry. Statistical analysis was performed by Mann–Whitney
U-test for non-parametric data distribution and correlation among the variables was examined by Spearman.
Results: Plasma tocopherol and tocotrienol were increased in vitamin E supplemented group as compared to
placebo group. Urine cotinine levels and serum α1-antitrypsin were significantly higher in smokers compared to
nonsmokers. Lymphocyte proliferation induced by PHA showed an increasing trend with palmvitee
supplementation in both smokers and nonsmokers. Natural killer cells were decreased; CD4+ cells and B cells were
increased in smokers compared to nonsmokers but were unaffected with vitamin E supplementation except in the
percentage of B cells which were increased in nonsmokers supplemented palmvitee compared to placebo.
CD4+/CD8+ ratio was increased in smokers compared to nonsmokers. The high TWBC count observed in smokers
correlated with the increased CD4+ and B cells.
Conclusions: Smoking caused alterations in certain immune parameters and palmvitee supplementation tended to
cause an increase in lymphocytes transformation test but had no effect on CD3+, CD4+, CD8+, NK cells and B cells
except B cells percentage in nonsmokers.
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Studies have reported that cigarette smoking cause
impairment of the immune function resulting in diseases
such as chronic obstructive lung disease, cardiovas-
cular disease and cancers [1,2]. Cigarette smoke alter
immunological functions that affect both humoral and* Correspondence: zakiah@medic.ukm.my
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reproduction in any medium, provided the orcell-mediated immune responses [3] such as elevated
white blood cell count, increased numbers of circulating
lymphocytes [4] and an abnormal T-cell profile [5].
Invariant natural killer (iNKT) that regulate and initiate
antitumor responses is reported reduced in smokers
[3,6]. Proteomics and transcriptomic studies also reveal
that protein and genes involves in immune function
were altered by smoking [7,8]. The alteration of immune
function in term of numbers and proportions of T-cell
subsets in the blood of smokers also depending on the
amount of cigarette smoking [5,9]. About 1015 free radicals
in the gas phase of each inhalation from cigarette smoked. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion [11], inducing single strand breaks in DNA, oxidizing
pulmonary proteins such as α1-proteinase inhibitor [12]
and also, nicotine in cigarette smoke may induce im-
munosuppression [13]. Studies on proliferative response
of human lymphocytes to phytohemagglutinin (PHA) and
LPS was reported decreased [14] and increased [3] in
cigarette smoking. Further studied by McCue et al. [15]
reported that hydroquinone and catechol in cigarette
smoke inhibit ribonucleotide reductase and reduces T cell
ability to proliferate and lead to cell cycle arrest. B lympho-
cyte proliferation induced by LPS was also inhibited by
cigarette smoke exposure in mice might be cause by the
increased superoxide and hydrogen peroxide generation of
cigarette smoke [16]. Although many studies reported the
harmful effect of smoking, mechanism to overcome this
problem is still not yet confirm.
Palm oil vitamin E (palmvitee) is a natural vitamin E
consists a mixture of 40% tocopherols and 60% tocotrienols
of which γ-tocotrienol is the major component. Each of
them consisting of four different forms: α-, β-, γ- and δ-.
Study claimed that tocotrienol give better antioxidant
activity [17] and immunomodulatory activity on T cell
proliferation and cytokine production [18] than tocopherol
but tocopherol is the most abundant in nature. Study
also has demonstrated that supplementation with alpha-
tocopherol alone increased the proliferation of lymphocytes
in the presence of LPS [19] and the combination from both
might give better effect for disease prevention, treatment or
specifically might increase immune response for smokers
to reduce the risk from obstructive lung disease, cardiovas-
cular disease and cancers.
Mechanism of vitamin E to increase immune response
is still not clearly understood. In healthy elderly persons,
the immunostimulatory effect of vitamin E may be
mediated due to the ability of vitamin E to decrease
prostaglandin (PGE2) production [20] and/or decrease
other lipid peroxidation products. In smokers isopros-
tanes which are stable products of lipid peroxidation
have been reported to increase [21] suggesting that
smokers may benefit from vitamin E supplementation.
The aim of this study is to determine the effect of palmvitee
supplementation on the immune status of smokers and
nonsmokers by measuring the parameters of cell mediated
immunity including lymphocytic activity.
Methods
Subjects
114 healthy males volunteers aged between 20-50 years
were recruited for the study. Each volunteer was briefed
on the objectives, design and protocol of the study
before informed consent was obtained. The experiments
were approved by the Ethics Committee, Faculty of
Medicine, UKM. All subjects were healthy, not on anyform of treatment and not taking any vitamin supplements
through the administration of a questionnaire and dietary
interview. The smokers group consisted of individuals who
have smoked for 5 years or more and smoking 10 cigarettes
or more per day.
Study design
A randomized single blind placebo controlled study was
designed consisting 58 smokers and 56 nonsmokers. The
58 smokers were divided into 2 groups where 28
received placebo while the other 30 received 200 mg/day
palmvitee (Palm Oil Research Institute of Malaysia,
PORIM). Each capsule of palmvitee contained 60% α-,
γ-, and δ-tocotrienols and 40% α-tocopherol. The fifty-six
nonsmokers were also divided into 2 groups of which 27
received placebo and another 29 received palmvitee
capsules. Blood was withdrawn at 0 week (before the start
of supplementation), 12 and 24 weeks of supplementation.
Urine was collected in the morning at 0 week and 24 weeks
for cotinine measurement. Urine samples were collected
into universal bottles containing a few crystals of thymol as
preservative. All the urine samples were stored at –20°C.
Blood (10 mls) was collected for lymphocyte transformation
test (LTT) and T cell profile.
Plasma tocopherol and tocotrienol determination
Plasma tocopherol and tocotrienol were determined by
the method of Meydani et al. [22]. Plasma samples were
deproteinized with ethanol containing 0.01% BHT. After
centrifugation, the supernatant was extracted with 5
volumes hexane (HPLC grade) (Merck, Germany). The
hexane layer was removed, dried and redissolved in ethanol.
HPLC separations were performed on a silica column
(250 × 4.6 mm) preceded by a guard silica column
(30 × 4.6 mm) (Supelco, USA) with a mobile phase of
hexane:isopropanol (99:1) at a flow rate 1.5 ml/min.
Cotinine to creatinine ratio (CCR) determination
Urinary cotinine concentrations were measured using
the method of Peach et al. [23]. The optical densities of
the specimens tested by the barbituric acid method were
measured at 506 nm using UV-160A visible spectropho-
tometer (Shimadzu, Japan) 20 min after reaction and
compared with the reading given by an aqueous solution of
10 μg/ml cotinine standard. The results were expressed as a
ratio of cotinine to creatinine (CCR) μg/mg to compensate
for the effect of diuresis. Creatinine was determined by the
Jaff reaction [24].
Serum α1-antitrypsin determination
α1-Antitrypsin in serum was determined using the
method published by Behring Diagnostic, Germany. N
Protein standard SY (human), N/T protein contol SY/M




















Figure 1 Total plasma vitamin E concentration in smokers and
nonsmokers.
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Lymphocyte transformation test (LTT)
Peripheral blood mononuclear cells (PBMN) were obtained
from diluted defibrinated blood by two-fold separation over
ficoll hypaque (Pharmacia, USA). The recovered cells were
washed, counted and adjusted to a concentration of 2 × 106
cell/ml in RPMI-1640 (Flow Labs, Sydney, Australia);
supplemented with 15% heat-inactivated AB serum and
20 ml kanamycin. Con A and PHA (Sigma, St. Louis, USA)
inducer cell T activity in 1:5, 1:10, 1:100 and 1:10, 1:50,
1:100, 1:200, 1:400 dilution respectively were set up in
culture medium supplemented with 15% AB serum. PBMN
were plated in 96-well disposable plates (Nunclon,
Denmark) in serial dilution with/without Con A and PHA.
PBMN were incubated for 72 hrs at 37°C in 5% CO2
incubator. Tritiated thymidine was added 4 hrs before
harvesting and the cells counted using a β counter (Wallac,
Finland). Dilution Con A 1:5 and dilution PHA 1:50 was
chosen for the analysis. Results were obtained in counts per
min (CPM) and changed to S.I. (Stimulation Index) = CPM
with mitogen/CPM without mitogen.
T and B cell enumeration
Total white blood cells, total number and the percentage of
lymphocyte in whole body were determined using coulter
counter T540. For determination of CD3+ cells (whole T
cells), CD19+ cells (B lymphocytes), CD16+ and CD56+ cells
(natural killer cells), CD4+ cells (T-helper cells), CD8+cells
(T-suppressor cells), cells were reacted with monoclonal
antibodies. All the monoclonal antibodies were purchased
from Becton Dickinson, (USA). The method used involved
lysing the erythrocytes with 10% lysing solution followed by
washing with PBS. The mixture was vortexed, centrifuged
and the supernatant removed. The cells were kept in 1%
formaldehyde in PBS and counted using a flow cytometer
(Becton Dickinson) and expressed as a percentage of the
total white blood cells. Becton Dickinson Simultest™ IMK-
Lymphocyte is a two-colour direct immunofluorescence
reagent kit for enumerating percentages of the mature
human leucocyte subsets in erythrocyte-lysed whole blood.
Statistical analysis
All results are expressed as the mean ± SD. Statistical
significance was calculated by using Mann–Whitney U-test
for nonparametric data distribution. Correlation among the
variables was examined by using Spearman. Data analysis
was performed using SPSS for Windows, version 17.
Results
Plasma total vitamin E level
There was no difference in total plasma vitamin E, tocoph-
erol and tocotrienol levels in smokers and nonsmokers atthe beginning of the study (Figure 1 & Table 1). After
palmvitee supplementation, both plasma tocopherol and
tocotrienol concentration were increased in smokers and
nonsmokers (p < 0.05) starting from 12 weeks until the end
of the experiment. Tocopherol concentration was higher in
plasma as compared to tocotrienol. Urinary cotinine and
serum α1-antitrypsin of smokers were significantly higher
(p < 0.05) compared to nonsmokers (Table 1) but no
changes were observed with supplementation. Urinary
cotinine levels were increased accordingly to the number
of cigarettes per day (Table 2).
Lymphocyte proliferation
There was no difference in the lymphocyte proliferation
after induction with mitogens PHA and Con A between
the different groups (smoking vs nonsmoking) (Table 3).
When the group of smokers divided into the number of
cigarettes smoked per day, it seems to reduce in S1
group and increased in S2 and S3 group (Table 2). But it
remained unaffected by palmvitee supplementation
(Table 3). But there seemed to be a trend for the
lymphocyte proliferation to increase at 24 weeks in the
palmvitee-supplemented group induced with PHA
(Table 3 & 4).
T-cell subsets and B cell percentage
Table 5 shows the baseline levels of white blood cells
counts, lymphocytes and T-cell subsets in smokers and
nonsmokers. Table 2 shows the baseline according the
number of cigarettes smoked per day. When comparing
immune parameters between smokers and nonsmokers,
WBC counts was higher in smokers (n = 58) compared
to nonsmokers (n = 56, p < 0.01) and unaffected by palm-
vitee supplementation (Table 6). No difference in the
total number and percentage of lymphocytes and CD3+
cells was observed before and after palmvitee supple-
mentation (Table 6). In separated group; S3, total CD3+
cells (T cell) increased significantly (p < 0.05) compared
to nonsmokers before supplementation (Table 2) and
remained unchanged in palmvitee-supplemented group
(Table 7). The percentage of B cells in smokers was
higher compared to nonsmokers (p < 0.0001) and also in
Table 1 The effects of palmvitee supplementation on plasma tocopherol and tocotrienol, α1-antitrypsin in serum and
urine cotinine levels in smokers and nonsmokers
Weeks Tocopherol (μg/ml plasma)
Nonsmokers Smokers
Placebo, n = 27 Palmvitee, n = 29 Placebo, n = 28 Palmvitee,n = 30
0 11.67 ± 3.19 11.75 ± 2.27 11.58 ± 3.19 11.39 ± 3.06
12 10.42 ± 2.17 14.22 ± 3.61* 10.27 ± 3.33 13.92 ± 4.17**
24 11.52 ± 2.94 14.56 ± 3.06* 11.53 ± 2.78 14.11 ± 3.89**
Tocotrienol (ng/ml)
0 62.49 ± 6.69 63.60 ± 5.67 60.05 ± 6.39 59.49 ± 4.21
12 63.50 ± 7.87 656.25 ± 142.50* 61.27 ± 3.62 570.22 ± 98.64**
24 60.65 ± 7.13 675.16 ± 150.00* 60.47 ± 3.00 587.68 ± 87.50**
CCR, (μg/mg creatinine)
n = 16 n = 19 n = 21 n = 20
0 0.052 ± 0.017 0.046 ± 0.017 0.927 ± 0.734# 0.941 ± 0.700#
24 0.058 ± 0.030 0.047 ± 0.017 0.866 ± 0.754# 1.179 ± 0.738#
α1-antitripsin(g/L serum)
n = 16 n = 19 n = 28 n = 30
0 1.48 ± 0.31 1.49 ± 0.34 1.99 ± 0.43# 1.94 ± 0.31#
24 1.47 ± 0.20 1.45 ± 0.24 1.69 ± 0.37 1.75 ± 0.39
Results are shown as mean ± SD. * indicates significant difference as compared to nonsmokers taking placebo (p < 0.01), ** indicates significant difference as
compared to smokers taking placebo (p < 0.01), # indicates significant difference as compared to nonsmokers (p < 0.0001), CCR represents cotinine:creatinine ratio.
Table 2 Baseline levels of lymphocytes in nonsmokers and smokers according to the number of cigarettes per day
Nonsmokers n = 56 S1 (n = 7) S2 (n = 34) S3 (n = 15)
Age (y) 34 ± 8 35 ± 5 35 ± 6 36 ± 6
Body mass index (kg/m2) 23.84 ± 3.99 24.11 ± 2.22 23.27 ± 3.26 23.55 ± 3.9822
Vitamin E μg/ml 11.76 ± 3.17 11.66 ± 3.24 11.66 ± 3.24 11.66 ± 3.98
α1-antitrypsin g/L serum 1.49 ± 0.32 1.98 ± 0.27* 1.96 ± 0.39* 1.94 ± 0.38*
CCR μg/mg creatinine 0.049 ± 0.017 0.268 ± 0.244* 0.974 ± 0.759* 1.13 ± 0.56*
PHA SI 70.54 ± 43.35 47.50 ± 34.63 89.05 ± 61.07 80.93 ± 55.85
Con A SI 54.73 ± 38.35 33.33 ± 17.07 66.94 ± 41.32 57.13 ± 23.01
White cell count (a.n. x 109/L) 7.99 ± 1.74 9.83 ± 2.60* 8.71 ± 2.16 9.55 ± 1.96*
Lymphocytes (a.n. x 109/L) 3.25 ± 0.74 3.77 ± 1.45 3.50 ± 1.00 3.58 ± 1.01
(%) 41.19 ± 7.76 37.68 ± 7.36 40.61 ± 6.74 39.83 ± 6.77
T cell (a.n. x 109/L) 2.05 ± 0.55 2.39 ± 0.10 2.36 ± 0.68 2.31 ± 0.71
(%) 62.76 ± 7.54 63.14 ± 11.31 64.64 ± 7.32 64.67 ± 7.83
B cell (a.n. x 109/L) 0.38 ± 0.20 0.67 ± 0.51* 0.52 ± 0.29* 0.54 ± 0.17*
(%) 11.13 ± 4.09 16.86 ± 6.20* 14.36 ± 4.20* 14.80 ± 4.28*
NK cells (a.n. x 109/L) 0.83 ± 0.35 0.67 ± 0.35 0.66 ± 0.31* 0.67 ± 0.33
(%) 25.31 ± 903 19.00 ± 8.25* 19.34 ± 6.67* 18.20 ± 7.16*
CD4+ (a.n. x 109/L) 0.92 ± 0.28 0.99 ± 0.30 1.18 ± 0.43* 1.14± 0.26*
(%) 28.27 ± 6.43 27.29 ± 4.42 33.44 ± 5.46 31.47 ± 5.82
CD8+ (a.n. x 109/L) 1.05 ± 0.39 1.17 ± 0.60 1.00 ± 0.34 1.049± 0.42
(%) 31.53 ± 7.52 30.00 ± 7.81 28.89 ± 6.92 29.33 ± 7.16
CD4+/CD8+ (%) 0.97 ± 0.44 0.987 ± 0.383 1.22 ± 0.37* 1.16 ± 0.42
S1 refers to < 9 cigarettes/d, S2; 10-19 cigarettes/d and S3; >20 cigarettes/d. * indicates significant difference as compared to nonsmokers (p < 0.05).
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Table 3 The effects of palmvitee supplementation on lymphocyte proliferative presented as stimulation index (S.I.)
after induction with mitogen, PHA and Con A in nonsmokers and smokers
Weeks Con A (S.I)
Non-smokers Smokers
Placebo, n = 27 Palmvitee, n = 29 Placebo, n = 28 Palmvitee, n = 30
0 49.77 ± 36.42 59.17 ± 40.10 69.21 ± 41.11 52.72 ± 30.00
12 48.19 ± 28.62 51.03 ± 28.78 47.70 ± 29.73 59.50 ± 34.18
24 46.92 ± 23.64 55.10 ± 27.23 42.21 ± 26.59 42.93 ± 31.75
PHA (S.I)
0 66.72 ± 48.82 73.97 ± 38.35 91.96 ± 62.15 73.45 ± 53.44
12 70.59 ± 39.43 72.14 ± 28.88 65.74 ± 34.69 75.27 ± 35.85
24 69.15 ± 28.32 86.41 ± 41.53 69.39 ± 38.07 77.10 ± 59.44
Results are shown as mean ± SD.
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(Table 2). After palmvitee supplementation, B cells
percentage was significantly increased in nonsmokers at
24 weeks (p < 0.05) but not in the smokers (Table 6). In
S1 and S3 palmvitee-supplemented groups there was a
trend of increment in B cells percentage. The increment
was correlated at 12 (r = 0.98, 0.87) and 24 weeks (r = 0.98,
0.96) respectively.
The percentage of NK cells were lower in smokers com-
pared to nonsmokers (p < 0.0001) at baseline (S1: p < 0.05,
S2: p < 0.005, S3: p < 0.01) and after palmvitee supplementa-
tion (Table 8 and Table 9). CD4+ in nonsmokers were lower
than smokers at the beginning of the study (p < 0.0001).
Total CD4+ in smokers were increased according to num-
ber of cigarettes per day. CD8+ percentage did not show
any significant difference among the groups. CD4+/CD8+
ratio was found to be significantly increased (p < 0.001) in
smokers compared to nonsmokers at baseline (Table 5)
and also in S2. However, no significant changes were
observed after palmvitee supplementation for both smokers
and nonsmokers (Table 9). There were also no changes
observed in these parameters at the different times of
supplementation.Table 4 The effects of palmvitee supplementation on lymphoc
induction with mitogen, PHA and Con A in nonsmokers and sm
Weeks S1
Placebo, n = 4 Palmvitee, n = 3 Placebo, n = 1
0 37.75 ± 15.73 24.50 ± 21.92 80.00 ± 48.12
12 39.25 ± 15.09 55.00 ± 35.59 53.50 ± 35.02
24 36.00 ± 32.65 22.00 ± 24.56 46.24 ± 28.03
0 58.00 ± 39.30 26.50 ± 6.36 73.17 ± 40.22
12 60.50 ± 24.96 51.67 ± 30.62 69.44 ± 40.09
24 59.25 ± 24.07 72.67 ± 69.82 74.71 ± 44.45
Results are shown as means ± SD. *
indicates significant difference as compared to nonsmokers.A significant positive correlation was observed in
smokers when comparing total white blood cells count
and total B cells count at 0 week (r = 0.57, p < 0.05)
(Table 2). Also a significant positive correlation was
found between TWBC count and total CD4+ cell count
before starting supplementation (r = 0.59, p < 0.05).
Discussion
Avoidance of tobacco and smoking cessation represent
the best method overcoming disease cases such as cancer,
chronic obstructive pulmonary disease (COPD) and
chronic heart disease (CHD). These approaches may not be
successful for some smokers. It might be due to their
attitude or self discipline to stop smoking. Supplementation
of vitamins or minerals can be used as an alternative to
increase the antioxidant levels and immune system in smo-
kers. In this study, report the effect of a randomized single-
blind placebo-controlled trial on the immune response
of cigarette smokers after palmvitee supplementation.
Supplementation of 200 mg/d palmvitee for 24 weeks to
the smokers and nonsmokers increase total plasma
vitamin E levels in plasma indicating compliance of the
study subjects. When this total vitamin E was separatedyte proliferative presented as stimulation index (S.I.) after
okers according to the number of cigarettes per day
S2 S3
7 Palmvitee,n = 19 Placebo, n = 7 Palmvitee,n = 8
Con A (SI)
55.26 ± 30.92 61.00 ± 15.41 53.75 ± 39.75
59.32 ± 40.01 39.29 ± 20.77 61.63 ± 28.52*
49.26 ± 35.55 36.00 ± 20.94 35.75 ± 26.99
PHA (SI)
70.21 ± 44.99 67.29 ± 29.84 44.60 ± 28.53
76.58 ± 35.20 60.29 ± 28.19 81.00 ± 38.53
78.47 ± 68.50 62.29 ± 27.49 75.50 ± 32.96
Table 5 Baseline levels of lymphocytes in smokers and nonsmokers
Nonsmokers n = 56 Smokers n = 58
Age (y) 34 ± 8 36 ± 6 NS
Body mass index (kg/m2) (kg/m2) 23.84 ± 3.99 23.52 ± 3.42 NS
Vitamin E μg/ml 11.76 ± 3.17 11.66 ± 3.24 NS
α1-antitrypsin g/L serum 1.49 ± 0.32 1.96 ± 0.37 P < 0.0000001
CCR μg/mg creatinine 0.049 ± 0.017 0.93 ± 0.31 P < 0.0000001
PHA SI 70.54 ± 43.35 77.50 ± 55.34 NS
Con A SI 54.73 ± 38.35 59.98 ± 36.29 NS
White cell count (a.n. x 109/L) 7.99 ± 1.74 9.06 ± 2.18 P < 0.01
Lymphocytes (a.n. x 109/L) 3.25 ± 0.74 3.58 ± 1.01 NS
(%) 41.19 ± 7.76 39.83 ± 6.77
. NS
T cell (a.n. x 109/L) 2.05 ± 0.55 2.31 ± 0.71 NS
(%) 62.76 ± 7.54 64.67 ± 7.83 NS
B cell (a.n. x 109/L) 0.38 ± 0.20 0.54 ± 0.29 P < 0.00001
(%) 11.13 ± 4.09 14.78 ± 4.48 P < 0.00001
NK cells (a.n. x 109/L) 0.83 ± 0.35 0.66 ± 0.31 P < 0.001
(%) 25.31 ± 903 19.00 ± 6.88 P < 0.0001
CD4+ (a.n. x 109/L) 0.92 ± 0.28 1.15± 0.38 P < 0.0001
(%) 28.27 ± 6.43 32.19 ± 5.73 P < 0.0001
CD8+ (a.n. x 109/L) 1.05 ± 0.39 1.04 ± 0.39 NS
(%) 31.53 ± 7.52 29.14 ± 6.97 NS
CD4+/CD8+ (%) 0.97 ± 0.44 1.18 ± 0.38 P < 0.0001
a.n. represents actual number.
Table 6 The effects of palmvitee supplementation on total white blood cells, lymphocytes, CD3+ cells, B lymphocyte, in
whole blood of nonsmokers and smokers
Weeks WBC Lymphocytes CD3+ cells B lymphocyte
a.n. x 109/L % a.n. x 109/L % a.n. x 109/L % a.n. x 109/L
Non-smokers (placebo, n = 27)
0 7.62 ± 1.89 41.96 ± 9.34 3.12 ± 0.77 63.54 ± 7.03 1.99 ± 0.60 10.19 ± 4.06 0.35 ± 0.26
12 7.29 ± 2.10 42.39 ± 6.12 3.04 ± 0.84 65.96 ± 6.70 2.00 ± 0.56 10.89 ± 3.56 0.33 ± 0.14
24 7.14 ± 1.53 41.85 ± 8.85 2.94 ± 0.72 64.27 ± 7.12 1.88 ± 0.50 11.00 ± 3.88 0.32 ± 0.12
Non-smokers (palmvitee, n = 29)
0 8.32 ± 1.55 40.52 ± 6.17 3.36 ± 0.70 62.07 ± 8.02 2.09 ± 0.52 11.97 ± 4.00 0.40 ± 0.13+
12 8.27 ± 2.08 40.39 ± 6.09 3.33 ± 0.74 62.72 ± 7.60 2.10 ± 0.55 12.45 ± 4.67 0.41 ± 0.16+
24 8.02 ± 1.50 38.05 ± 5.80+ 3.05 ± 0.77 61.66 ± 14.23 1.96 ± 0.55 13.72 ± 4.53+ 0.41 ± 0.15+
Smokers (placebo, n = 28)
0 9.74 ± 2.31 40.44 ± 7.39 3.91 ± 1.14 63.50 ± 7.87 2.47 ± 0.71 15.54 ± 5.06 0.64 ± 0.38
12 9.38 ± 2.45 40.53 ± 8.20 3.76 ± 1.16 63.82 ± 8.34 2.40 ± 0.65 16.14 ± 4.70 0.59 ± 0.33
24 8.81 ± 2.30 38.00 ± 8.68 3.30 ± 1.04 66.11 ± 10.78 2.14 ± 0.63 15.25 ± 4.40 0.52 ± 0.29
Smokers (palmvitee, n = 30)
0 8.43 ± 1.86 39.27 ± 6.20 3.27 ± 0.75 65.77 ± 7.75 2.16 ± 0.69 14.06 ± 3.81 0.45 ± 0.15
12 8.13 ± 2.29 40.07 ± 7.04 3.19 ± 0.72 66.27 ± 6.59 2.13 ± 0.58 14.30 ± 4.09 0.45 ± 0.16
24 8.06 ± 2.10 37.68 ± 7.29 3.01 ± 0.88 66.83 ± 7.28 2.02 ± 0.69 14.40 ± 4.03 0.43 ± 0.16
Results are shown as mean ± SD. + indicates significant difference as compared to non-smokers taking placebo (p < 0.05), a.n. represents actual number.
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Table 7 The effects of palmvitee supplementation on total white blood cells, lymphocytes, CD3+ cells, B lymphocyte, in
whole blood of nonsmokers and smokers according to the number of cigarettes per day
Weeks WBC Lymphocytes CD3+ cells B lymphocyte
a.n. x 109/L % a.n. x 109/L % a.n. x 109/L % a.n. x 109/L
S1; 1-9 cigarettes/d (placebo, n = 4)
0 9.80 ± 2.07 37.25 ± 8.59 3.79 ± 1.65 59.75 ± 13.25 2.21 ± 0.81 17.75 ± 8.42 0.76 ± 0.70
12 10.05 ± 3.10 38.63 ± 10.59 3.94 ± 2.08 58.00 ± 11.58 2.36 ± 0.93 18.00 ± 6.38 0.81 ± 0.73
24 9.43 ± 2.67 36.05 ± 10.39 3.56 ± 1.92 54.75 ± 21.93 1.91 ± 0.96 15.25 ± 6.90 0.63 ± 0.52
S1; 1-9 cigarettes/d (palmvitee, n = 3)
0 9.87 ± 3.72 38.27 ± 7.15 3.75 ± 1.52 67.67 ± 8.14 2.62 ± 1.40 15.67 ± 2.31 0.56 ± 0.13
12 6.73 ± 1.10 39.57 ± 5.75 2.64 ± 0.35 69.00 ± 6.08 1.80 ± 0.11 17.67 ± 4.04 0.48 ± 0.16
24 6.53 ± 0.76 35.20 ± 11.15 2.29 ± 0.70 65.33 ± 5.77 1.47 ± 0.35 19.00 ± 2.65 0.45 ± 0.18
S2; 10-19 cigarettes/d (placebo, n = 17)
0 9.31 ± 2.53 42.85 ± 6.63 3.96 ± 1.20 64.24 ± 6.28 2.54 ± 0.76 14.82 ± 4.25 0.63 ± 0.37
12 8.92 ± 2.61 41.19 ± 7.34 3.62 ± 0.99 65.71 ± 7.08 2.38 ± 0.62 15.47 ± 3.68 0.52 ± 0.28
24 8.22 ± 2.38 40.26 ± 8.70 3.23 ± 0.95 68.12± 7.03 2.18 ± 0.63 14.82 ± 3.59 0.50 ± 0.2
S2; 10-19 cigarettes/d (palmvitee, n = 19)
0 8.17 ± 1.65 38.59 ± 6.35 3.10 ± 0.54 65.00 ± 8.30 2.00 ± 0.51 13.95 ± 4.24 0.42 ± 0.14
12 8.11 ± 2.36 38.51 ± 7.34 3.02 ± 0.60 65.74 ± 7.34 2.01 ± 0.52 13.63 ± 3.52 0.41 ± 0.14
24 7.64 ± 2.02 37.22 ± 8.70 2.81 ± 0.74 67.26 ± 7.01 1.89 ± 0.55 13.37 ± 3.99 0.38 ± 0.15
S3; >20 cigarettes/d (placebo, n = 7)
0 10.76 ± 1.75 36.42 ± 7.01 3.87 ± 0.81 63.86 ± 8.65 2.46 ± 0.58 16.00 ± 5.16 0.60 ± 0.17
12 10.11 ± 1.58 39.99 ± 9.93 3.99 ± 1.10 62.57 ± 8.83 2.49 ± 0.68 16.71 ± 6.26 0.64 ± 0.23
24 9.90 ± 1.58 33.66 ± 6.62 3.31 ± 0.77 67.71± 7.09 2.18 ± 0.44 16.29 ± 5.22 0.50 ± 0.18
S3; >20 cigarettes/d (palmvitee, n = 8)
0 8.50 ± 1.54 41.23 ± 6.12 3.50 ± 0.70 66.88 ± 7.95 2.37 ± 0.51 13.75 ± 3.97 0.48 ± 0.13
12 8.70 ± 2.06 43.96 ± 6.03 3.79 ± 0.74 66.50 ± 7.53 2.55 ± 0.55 14.63 ± 4.63 0.55 ± 0.16
24 9.64 ± 1.49 39.71 ± 5.75 3.75 ± 0.76 66.38 ± 14.10 2.54 ± 0.54 15.13 ± 4.49 0.56 ± 0.15
Results are shown as mean ± SD.
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were also increased with supplementation. The concen-
tration of tocopherol was higher in plasma as compared
to tocotrienol because of the action of hepatic α-tocoph-
erol transfer protein (α-TTP). α-TTP selectively chooses
α-tocopherol for enrichment of nascent very low density
lipoproteins (VLDL) [25]. During VLDL catabolism in
the circulation, α-tocopherol is transferred to all the
other plasma lipoproteins. Although, the dose used in
the study was 200 mg/d vitamin E, only 40% of palmvi-
tee is α-tocopherol while 60% consisted of tocotrienols.
Whereas tocotrienols are transported and distributed
differently in different tissues according to their roles in
cellular function [26]. For example, skin contained 15%
tocotrienols and only 1% γ-tocopherol. Although, the
accumulation of tocotrienols may be low, but they may
exert substantial antioxidant effects [27]. Studied by
Maniam et al. [28] in rats showed that tocotrienol gives
better protective effect against free radical damage in the
femur compared to alpha-tocopherol. Reported by Saito
et al. [29] the uptake of alpha-tocotrienol in Jurkat cellswas found to be 2.2 fold higher than alpha-tocopherol
after incubation for 72 hours. Also, it was found that the
initial rate of cellular uptake of alpha-tocotrienol was
70-fold higher than alpha-tocopherol [30].
There was no significant difference in plasma vitamin E
levels for tocopherol and tocotrienol between smokers and
nonsmokers was observed. Previous study reported by
Wallstrom et al. [31] demonstrated that serum vitamin E
levels (α-tocopherol) were similar in smokers vs. nonsmo-
kers and only associated with dietary supplements, not with
foods. Whereas when the smokers were grouped according
to number of cigarettes smoked per day, it gave different
result. Antioxidant vitamin intakes were significantly higher
in nonsmokers than in light (1-20 cigarettes/day) and heavy
smokers (>20 cigarettes/day) [32]. Exposure of human
plasma in vivo to the gas phase of cigarette smoke will
cause degradation of vitamin E [33]. Fractional disappear-
ance rate of α-tocopherol in smokers were faster, and its
half-lives were shorter than in nonsmokers [34]. This may
lead to insufficient levels of vitamin E and was suggested to
have an effect on the immune status of these individuals.
Table 8 The effects of vitamin E supplementation on NK cells, CD4+ cells, CD8+ cells and CD4+/CD8+ in whole blood of
nonsmokers and smokers
Weeks NK cells CD4+ CD8+ CD4+/CD8+
% a.n. x 109 % a.n. x 109 % a.n. x 109 %
Non-smokers (placebo, n = 27)
0 25.00 ± 9.44 0.73 ± 0.34 29.07 ± 6.16 0.91 ± 0.28 31.69 ± 7.41 0.99 ± 0.41 0.99 ± 0.40
12 22.85 ± 7.74 0.70 ± 0.35 30.81 ± 6.75 0.94 ± 0.35 31.19 ± 8.03 1.00 ± 0.36 1.02 ± 0.46
24 24.72 ± 7.94 0.75 ± 0.32 31.27 ± 6.87 0.92 ± 0.32 32.07 ± 8.30 0.94 ± 0.36 1.07 ± 0.48
Non-smokers (palmvitee, n = 29)
0 25.59 ± 8.80 0.86 ± 0.36 27.55 ± 6.68 0.92 ± 0.29 31.38 ± 7.75 1.07 ± 0.30 0.96 ± 0.48
12 24.59 ± 8.45 0.81 ± 0.33 27.62 ± 7.72 0.92 ± 0.33 30.28 ± 6.75 1.03 ± 0.35 0.97 ± 0.47
24 24.72 ± 8.78 0.72 ± 0.42 30.17 ± 9.35 0.90 ± 0.30 31.00 ± 6.72 0.96 ± 0.37 1.03 ± 0.53
Smokers (placebo, n = 28)
0 19.54 ± 7.50+ 0.76 ± 0.39 32.18 ± 5.98+ 1.24 ± 0.44+ 27.82 ± 5.36+ 1.08 ± 0.34 1.22 ± 0.38+
12 19.46 ± 8.55+ 0.75 ± 0.45 33.07 ± 7.32+ 1.23 ± 0.39+ 27.46 ± 6.01+ 1.05 ± 0.36 1.24 ± 0.40+
24 19.18 ± 10.93+ 0.64 ± 0.46 35.14 ± 7.93+ 1.14 ± 0.44+ 28.04 ± 7.34 0.93 ± 0.27 1.25 ± 0.36+
Smokers (palmvitee, n = 30)
0 18.48 ± 6.32++ 0.58 ± 0.17++ 32.20 ± 5.54++ 1.03 ± 0.29 30.37 ± 8.09 1.00 ± 0.45 1.13 ± 0.39
12 17.87 ± 6.50++ 0.55 ± 0.21++ 33.20 ± 5.56++ 1.07 ± 0.29++ 30.17 ± 8.21 0.98 ± 0.42 1.21 ± 0.44++
24 19.03 ± 7.82 0.57 ± 0.27 33.90 ± 5.56++ 1.03 ± 0.37 30.67 ± 7.61 0.92 ± 0.38 1.19 ± 0.43++
Results are shown as mean ± SD. a.n. represents actual number. + indicates significant difference as compared to nonsmokers taking placebo (p < 0.05). ++
indicates significant difference as compared to nonsmokers taking palmvitee (p < 0.05).
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double-blind study using healthy elderly individuals for
235 days that after varying the dose of dl-α-tocopherol
supplementation, it was found that a dose of 200 mg/d
caused the highest percent increase in delayed type hyper-
sensitivity, suggesting that 200 mg/d might be a threshold
level for the immunostimulatory effect of vitamin E. It also
supported by Lee and Man-Fan [19] in supplementing
healthy ethnic Chinese men and women with dl-α-tocoph-
erol E (233 mg/d) for 28 days.
Comparison of lymphocyte proliferation measured as
stimulation index induction with mitogen PHA and Con
A did not show any differences between smokers and
nonsmokers were also unaffected by supplementation of
palmvitee (Tables 5 and 3). But lymphocyte response to
the mitogen PHA also seemed to be increased with
palmvitee supplementation. This observation differed
from that reported by Meydani et al. [18] where only
Con A stimulated mitogenic response increased in the
vitamin E supplemented group. Reported by Lee and
Man-Fan Wan [19] supplementation of vitamin E in
healthy individual subjects increased lymphocyte prolif-
eration both in the presence and absence of mitogen
challenge and also the increasing of immunological sub-
sets. But there was a confounding factor (gender) be-
cause hormonal changes play a role in the regulation of
the immune response [36] Studied by Radhakrishnan
et al. [37] in healthy human volunteers supplemented
with 200 mg of tocotrienol-rich fraction or alpha-tocopherol showed no changes observed in the produc-
tion of IL-4 or interferon-γ by Con A-stimulated lym-
phocytes. In this study, palmvitee supplementation also
did not affect T-cell subsets and a similar finding was
reported by Meydani et al. [35]. Cigarette smoke is
reported to contain many oxidising species [38] and
smokers incur a high and sustained free radical load.
Smokers may need a higher dose of vitamin E than
200 mg/day to overcome the free radical load and in-
crease the immune system. A study using monkeys have
shown that a low dose cigarette smoke (human equiva-
lent of 1 pack day) affect the response of spleens cells to
either PHA or LPS whereas a heavy dose (human
equivalent of 3 pack day) for 4-8 years caused a signifi-
cant reduction in their natural NK-mediated lytic activity
and a decreased response to Con A [39]. It is possible
that the subjects were not heavy smokers to cause any
changes to the lymphocytes proliferation activity. Stud-
ied by Thatcher et al. [40] showed that at the higher
dose of mainstream cigarette smoke (MSC) exposure
(600 mg/m3 total suspended particulates (TSP) sup-
presses the antigen-specific proliferation and cytokine
production by T-cell than low dose of MSC (77 mg/m3
TSP).
Difference between smokers and nonsmokers in baseline
volumes of certain immune parameters measured were also
observed these include higher total white cell counts, CD4+
cells and CD4+/CD8+ in smokers and lower number of
natural killer cells. These differences in T-cells populations
Table 9 The effects of vitamin E supplementation on NK cells, CD4+ cells, CD8+ cells and CD4+/CD8+ in whole blood of
nonsmokers and smokers according to the number of cigarettes per day
Weeks NK cells CD4+ CD8+ CD4+/CD8+
% a.n. x 109 % a.n. x 109 % a.n. x 109 %
S1; 1-9 cigarettes/d (placebo, n = 4)
0 21.50 ± 9.57 0.78 ± 0.45 26.25 ± 5.44 0.93 ± 0.22 28.25 ± 9.11 1.09 ± 0.51 1.05 ± 0.50
12 22.00 ± 12.73 0.87 ± 0.65 25.25 ± 3.20 0.96 ± 0.41 27.25 ± 9.25 1.07 ± 0.55 1.02 ± 0.43
24 31.75 ± 22.78 1.09 ± 0.97 23.75 ± 7.27 0.83 ± 0.40 25.50 ± 11.85 0.87 ± 0.42 0.99 ± 0.22
S1; 1-9 cigarettes/d (palmvitee, n = 3)
0 15.67 ± 6.11 0.53 ± 0.04 28.67 ± 3.06 1.07 ± 0.43 32.33 ± 6.66 1.28 ± 0.79 0.90 ± 0.20
12 13.67 ± 1.53 0.37 ± 0.09 34.67 ± 2.08 0.92 ± 0.16 30.67 ± 4.73 0.79 ± 0.46 1.16 ± 0.23
24 18.33 ± 6.43 0.45 ± 0.25 29.67 ± 3.79 0.69 ± 0.26 31.00 ± 6.24 0.68 ± 0.10 0.99 ± 0.29
S2; 10-19 cigarettes/d (placebo, n = 17)
0 19.59 ± 6.75 0.76 ± 0.38 34.18 ± 6.15 1.37 ± 0.52 27.76 ± 4.83 1.07 ± 0.32 1.30 ± 0.39
12 20.12 ± 8.37 0.71 ± 0.39 35.65 ± 7.55 1.29 ± 0.41 27.24 ± 5.84 1.01 ± 0.29 1.33 ± 0.40
24 17.47 ± 6.69 0.55 ± 0.25 37.06 ± 7.04 1.21 ± 0.49 28.94 ± 7.26 0.93 ± 0.25 1.31 ± 0.38
S2; 10-19 cigarettes/d (palmvitee, n = 19)
0 19.11 ± 6.78 0.57 ± 0.20 32.79 ± 4.85 1.02 ± 0.26 29.89 ± 8.38 0.93 ± 0.35 1.15 ± 0.34
12 18.42 ± 7.27 0.53 ± 0.20 33.05 ±5.78 1.01 ± 0.26 30.05 ± 7.71 0.93 ± 0.33 1.20 ± 0.45
24 18.58 ± 7.88 0.52 ± 0.26 34.95 ± 5.02 0.99 ± 0.34 30.74 ± 7.26 0.85 ± 0.28 1.23 ± 0.47
S3; >20 cigarettes/d (placebo, n = 7)
0 18.29 ± 9.01 0.74 ± 0.47 30.71 ± 2.81 1.18 ± 0.21 27.71 ± 5.06 1.08 ± 0.35 1.15 ± 0.30
12 18.43 ± 7.46 0.76 ± 0.52 31.29 ± 4.57 1.21 ± 0.27 28.14 ± 5.30 1.13 ± 0.42 1.14 ± 0.38
24 16.14 ± 5.84 0.61 ± 0.39 37.00 ± 4.86 1.15 ± 0.25 27.29 ± 4.96 1.01 ± 0.45 1.24 ± 0.37
S3; >20 cigarettes/d (palmvitee, n = 8)
0 18.13 ± 8.72 0.60 ± 0.36 32.13 ± 6.63 1.09 ± 0.29 30.75 ± 7.68 1.09 ± 0.37 1.17 ± 0.48
12 18.13 ± 8.37 0.67 ± 0.32 33.00 ± 7.65 1.24 ± 0.33 30.25 ± 6.69 1.17 ± 0.35 1.25 ± 0.46
24 20.38 ± 8.70 0.73 ± 0.42 33.00 ± 9.27 1.24 ± 0.29 30.38 ± 6.66 1.17 ± 0.37 1.19 ± 0.15
Results are shown as mean ± SD.
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countries. For example, the results obtained by Tollerud
et al. [41] have shown that CD4+ T-cells but not in CD8+
T-cells, CD3+ T-cells or CD19+ B-cells were higher in
smokers compared to nonsmokers. Other T-cells subsets
such as memory and naïve T-cells subpopulations were
also increased in smokers [42]. The reduced NK cell
observed in smokers is in agreement with another study
by Moszczynski et al. [43]. The reduction of NK cells in
smokers correlated with a reduction in immune surveil-
lance against tumors and viral infections [44] and maybe
a contributing factor to development of malignancy.
Studied by Lu et al. [45] in mice showed the consistent
finding where that cigarette smoke suppressed NK activa-
tion and lead cell transformation and cancer formation.
But other several studies reported that there were no
changes in NK cells [46,47] and no significant differences
in NK cell percentage but NK tumoricidal activity was
significantly higher. Tanigawa et al. [42] reported an
increase in CD4+ cells in smokers compared with non-
smokers which was in agreement with the results obtainedin this study. They also reported that the increase in the
number of CD4 +CD29+ (helper inducer) T lymphocytes
is responsible for the increase in total CD4+ T lympho-
cytes in smokers. This may be due to continuous local
inflammation in the respiratory system induced by chronic
smoking. Another possible explanation is that antigenic
substances present such as glycoproteins present in some
cigarettes may act as an antigen leading to an increase in
CD4 +CD29+ T lymphocytes as the tobacco glycoprotein
induces the production of interleukin (IL) 1 alpha and IL-1
beta by peripheral blood and adherent cells. Tobacco
glycoprotein is a potent immunostimulatory compound
that has been isolated from cigarette smoke [48] where it
has been shown to be antigenic in humans.
The B cells percentage was higher in smokers than
nonsmokers and this was also reported by Mili et al. [49]
which was attributed to an increase in CD4+ in smokers. It
is possible that in this study, CD4+ was induced by tobacco
glycoprotein and provided a signal to B cells to produce
antibodies. Palmvitee supplementation was found to
increase B cells in nonsmokers only. This observation could
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which acts by a reducing prostaglandins synthesis and or
decreasing free radical formation [50]. This finding
however differed with that of Meydani et al. [35] who
reported that vitamin E supplementation had no effect on
immunoglobulin levels or levels of T and B cells in
healthy elderly subjects. The difference observed could be
due to the different age groups of the subjects and it is
well established that the immune response is influenced
by age. The increment of B cells and CD4+ cell correlated
with the higher TWBC in smokers.
A similar pattern was observed when the immune
parameters were measured in terms of packed years of
exposure rather than cigarettes per day. Tanigawa et al.
[42] also reported higher CD4+ lymphocytes in smokers
but no differences in CD8+, CD19+ B lymphocytes and
CD16+ NK cells. The findings rather of the two parameters
were however contrary to our present findings where B
lymphocyte was raised while NK cells were decreased.
However, Tanigawa et al. [42] reported the results of only 8
male smokers whereas in this study other were 58 smokers
which were also age-matched with the nonsmokers.
Another studied by Moszczynski et al. [43] who grouped
the subjects in terms of less and over 10 years of smoking
gave different pattern of result. CD4+, CD8+ and NK cells
increased in smoked-group less than 10 years whereas
reduced in smoked-group over 10 years. No changes
were observed in B lymphocytes. The highly significant
(p < 0.001) reduction in NK cells could also explain
increased risk to cancer formation due to a decrease in
cellular mediated immune protection/surveillance.
It was interesting to note that while supplementation
had no effect on the lymphocyte proliferation as well as
on total white cells, total lymphocytes, and total T-cells
in both smokers and nonsmokers, palmvitee supplemen-
tation was observed to cause an increase (p < 0.05) in
the number of B-cells in nonsmokers. This was — betted
to the response beneficial effect of palmvitee in enhan-
cing immune response. However, in smokers B-cells
numbers were unaffected by supplementation possibly
because of the already raised basal values caused by
smoking. This is the only immune parameter which was
affected by palmvitee supplementation. Other parameter
remained low with supplementation, whilst the high
CD4+ and lower CD8+ percentage of cells remained
unchanged with supplementation. This lack of effect
could be due to the dosage used which was only
200 mg/d compared to 800 mg/d as reported by Meydani
et al. [35] in his study in the elderly population.
Urinary cotinine/creatinine standardized as μg/mg, a
stable metabolite of nicotine, were increased significantly
in smokers indicating the active smoking status of subjects
compared to nonsmokers [51]. Obviously when smoking
group divided into the number of cigarette smoked perday urinary cotinine increase accordingly to the number
of cigarette smoked per day. Also serum α1-antitrypsin
was significantly higher in smokers, again indicating the
smoking status of these subjects. Elevations in α1-anti-
trypsin were significantly associated with the impairment
of pulmonary function to smoking. Supplementation with
palmvitee demonstrated no changes for both CCR and
α1-antitrypsin concentration in smokers as compared to
the placebo group. It showed that might be there were no
interaction between CCR and α1-antitrypsin with palmvitee
that can reduced their level in the blood.
Conclusions
In conclusions, cigarette smoking is associated with an
increase in CD4+ cell, B cells and a decrease in CD8+
and NK cells. An increase in CD4+ cell and B cells cor-
related with higher TWBC counts in smokers. Although
vitamin E increased in supplemented smokers, there
were no changes in T-cell profile except for an increase in
the number of B cells in nonsmokers. In smokers, prolifera-
tion of lymphocytes after stimulation by PHA tended to be
increased with time of vitamin E supplemented but not
after exposure to mitogen Con A. Vitamin E might not
reach the optimal levels to modulate or improve the
immune status.
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